Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.

Burmester, Gerd; Drescher, Edit; Hrycaj, Pawel; Chien, David; Pan, Zhiying; Cohen, Stanley

Burmester, Gerd; Drescher, Edit; Hrycaj, Pawel; Chien, David; Pan, Zhiying; Cohen, Stanley.

Burmester G; Department of Rheumatology and Clinical Immunology, Free University and Humboldt University Berlin, Charité University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany. gerd.burmester@charite.de.
Drescher E; Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary.
Hrycaj P; Rheumatology, Koscian Municipal Hospital, Koscian, Poland.
Chien D; Amgen Inc., Thousand Oaks, CA, USA.
Pan Z; Amgen Inc., Thousand Oaks, CA, USA.
Cohen S; Metroplex Clinical Research Center, Dallas, TX, USA.

Clin Rheumatol ; 39(11): 3527, 2020 Nov.

Article en En | MEDLINE | ID: mdl-32965602

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Año: 2020 Tipo del documento: Article